Showing 281-300 of 498 for: Cochrane Systematic Reviews > Neurologic 
- Metal protein attenuating compounds for the treatment of Alzheimer's dementia
Cochrane Systematic Reviews, 20-Feb-2014
Alzheimer's dementia (AD) may be caused by the formation of extracellular senile plaques comprised of beta-amyloid (Aß). In vitro and mouse model studies have demonstrated that metal protein attenuating compounds (MPACs) promote the solubilisation and cle
- Methadone for cancer pain
Cochrane Systematic Reviews, 8-Feb-2017
This is an updated review originally published in 2004 and first updated in 2007. This version includes substantial changes to bring it in line with current methodological requirements. Methadone is a synthetic opioid that presents some challenges in dose
- Methotrexate for multiple sclerosis
Cochrane Systematic Reviews, 5-Sep-2010
Methotrexate is a potent immunosuppressant which in theory could reduce relapse rates and delay disease progression in multiple sclerosis (MS). Subsequently, clinical trials of methotrexate have been conducted in people with MS.
- Metrifonate for Alzheimer's disease
Cochrane Systematic Reviews, 18-Mar-2008
Metrifonate is a long-acting irreversible cholinesterase inhibitor, originally used to treat schistosomiasis. Its potential to enhance central nervous system cholinergic neurotransmission led to clinical trials for the treatment of people with Alzheimer's
- Milnacipran for pain in fibromyalgia in adults
Cochrane Systematic Reviews, 22-May-2019
This is an updated version of the original Cochrane review published in Issue 3, 2012. That review considered both fibromyalgia and neuropathic pain, but the efficacy of milnacipran for neuropathic pain is now dealt with in a separate review.
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia
Cochrane Systematic Reviews, 19-Mar-2018
Antipsychotic (neuroleptic) medication is used extensively to treat people with chronic mental illnesses. Its use, however, is associated with adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetiti
- Mitoxantrone for multiple sclerosis
Cochrane Systematic Reviews, 23-Oct-2013
Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients.
- Monoamine oxidase B inhibitors for early Parkinson's disease
Cochrane Systematic Reviews, 14-Nov-2011
Monoamine oxidase B (MAO-B) inhibitors slow disease progression in Parkinson's disease (PD) but clinical trials have produced conflicting results.
- Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
Cochrane Systematic Reviews, 7-Oct-2009
It has been postulated that monoamine oxidase B (MAO-B) inhibitors alter disease progression in Parkinson's disease (PD) but trials have produced conflicting results.
- Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome
Cochrane Systematic Reviews, 8-Mar-2012
Fibromyalgia (FM) syndrome is a chronic condition of unknown aetiology characterised by musculoskeletal pain that often co-exists with sleep disturbance, cognitive dysfunction and fatigue. Patients often report high disability levels and poor quality of l
- Monoaminergic agonists for acute traumatic brain injury
Cochrane Systematic Reviews, 6-Dec-2010
Although there have been considerable gains in understanding the cascade of events that lead to secondary injury after traumatic brain injury (TBI), efforts to translate this understanding into new therapeutic, so-called neuroprotective approaches, have s
- Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease
Cochrane Systematic Reviews, 9-Nov-2011
Multidisciplinary care (MDC) is increasingly thought to be an important means of symptomatic and supportive management for motor neuron disease (MND) but the evidence base for its effectiveness is unclear. This is the first update of a review first publis
- Multidisciplinary care for Guillain-Barré syndrome
Cochrane Systematic Reviews, 7-Sep-2010
Guillain-Barré syndrome is a significant cause of new long-term disability, which is thought to be amenable to multidisciplinary care, but the evidence base for its effectiveness is unclear.
- Multi‐disciplinary rehabilitation for acquired brain injury in adults of working age
Cochrane Systematic Reviews, 22-Dec-2015
Evidence from systematic reviews demonstrates that multi-disciplinary rehabilitation is effective in the stroke population, in which older adults predominate. However, the evidence base for the effectiveness of rehabilitation following acquired brain inju
- Multidisciplinary rehabilitation for adults with multiple sclerosis
Cochrane Systematic Reviews, 8-Nov-2011
Multidisciplinary (MD) rehabilitation is an important component of symptomatic and supportive treatment for Multiple Sclerosis (MS), but evidence base for its effectiveness is yet to be established.
- Muscle relaxants for non-specific low-back pain
Cochrane Systematic Reviews, 27-Mar-2017
The use of muscle relaxants in the management of non-specific low back pain is controversial. It is not clear if they are effective, and concerns have been raised about the potential adverse effects involved.
- Music therapy for people with autism spectrum disorder
Cochrane Systematic Reviews, 17-Jun-2014
The central impairments of people with autism spectrum disorder (ASD) affect social interaction and communication. Music therapy uses musical experiences and the relationships that develop through them to enable communication and expression, thus attempti
- Music‐based therapeutic interventions for people with dementia
Cochrane Systematic Reviews, 23-Jul-2018
Dementia is a clinical syndrome with a number of different causes which is characterised by deterioration in cognitive, behavioural, social and emotional functions. Pharmacological interventions are available but have limited effect to treat many of the s
- Natalizumab for relapsing remitting multiple sclerosis
Cochrane Systematic Reviews, 29-Aug-2011
Natalizumab (NTZ) (Tysabri®) is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier, thus reducing inflammation in central nervous system, and has been approved worldwide for the treatment of relapsing-remitting multiple
- Neuraxial anaesthesia for lower‐limb revascularization
Cochrane Systematic Reviews, 29-Jul-2013
Lower-limb revascularization is a surgical procedure that is performed to restore an adequate blood supply to the limbs. Lower-limb revascularization surgery is used to reduce pain and sometimes to improve lower-limb function. Neuraxial anaesthesia is an
